Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1997-09-19
2001-08-14
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S023000, C536S005000
Reexamination Certificate
active
06274558
ABSTRACT:
BACKGROUND OF THE INVENTION
Digitalis, digoxin, ouabain and related substances are cardiac glycosides derived from plants. The main pharmacodynamic property of cardiac glycosides is the ability to increase the force of myocardial contraction in a dose-dependent manner (positive inotropic effect). The most probable explanation for the direct positive inotropic effect is the ability of cardiac glycosides to inhibit membrane-bound Na
+
, K
+
-activated adenosine triphosphatase (Na
+
, K
+
-ATPase) (Hoffman, B. F. and J. T. Bigger, Jr., “Digitalis and Allied Cardiac Glycosides” in
The Pharmacological Basis of Therapeutics
, eds. Goodman and Gilman, p. 732, (1980)). The hydrolysis of adenosine triphosphate (ATP) by this enzyme provides the energy for the sodium potassium pump.
Relatively little is known about the endogenous regulation of Na
+
, K
+
-ATPase. Catecholamines (Phillis, J. W.,
Cell, Tissue and Organ Cultures in Neurobiology
, pp. 93-97 (1978); Horwitz, B. A.,
Fed. Proc
., 38:2170-2176 (1979)), thyroid hormone (Smith, T. J. and I. S. Edelman,
Fed. Proc
., 38:2150-2153 (1979)), aldosterone (Rossier, B. C., et al., Science, 12:483-487 (1987)), linoleic and linolenic acids (Bidard, J. N., et al.,
Biochem. Biophys. Acta
., 769:245 (1984); Tamura, M., et al.,
J. Biol. Chem
., 260:9672 (1985); and vanadium (Cantley, L. C., Jr., et al.,
J. Biol. Chem
., 243:7361-7368 (1978)) have all been linked to either direct or indirect effects on enzyme activity.
Many researchers have tried to isolate a specific endogenous inhibitor of plasma membrane Na
+
, K
+
-ATPase similar to digitalis or ouabain, but of mammalian origin, by measuring immunoreactivity in plasma, to the digoxin radioimmunoassay in situations where the inhibitor might be elevated. Klingsmueller et al. found digitalis like immunoreactivity in the urine of Na
+
-loaded normal human subjects (Klingsmueller, et al.,
Klin. Wochenschr
., 60: 1249-1253 (1982)). Graves, S. W., et al. made a similar observation in the plasma of uremic subjects (Graves, S. W., et al.,
Ann. Intern. Med
., 99:604-608 (1983)).
The definitive structure of plasma, urinary or tissue inhibitor of Na
+
, K
+
-ATPase is not known (Haupert, G. T., Jr., in
The Na
+
K
+
-
Pump, Part B: Cellular Aspects
; Skou, J. C., et al., Eds., p. 297-320 (1988)). Furthermore, the degree to which various candidate compounds are truly “digitalis-like” in either structure or function remains controversial, since even those substances characterized in the greatest biochemical detail manifest some differences with the cardiac glycosides, digitalis and ouabain (Carilli, C. T., et al.,
J. Biol. Chem
., 260: 1027-1031 (1985); Crabos, M., et al.,
Eur. J. Biochem
., 162:129 (1987); Tamura, M., et al.,
Biochem
., 27:4244-4253 (1988)).
For example, the digitalis-like factor (DLF) isolated by Graves cross-reacts with antidigoxin antibodies (Graves, S. W., U.S. Pat. No. 4,780,314)). However, DLF has never been shown to be a physiologic inhibitor, as would be expected of an endogenous regulator. By physiologic is meant an inhibitor that has a very high binding affinity for the enzyme; reversibly binds and inhibits; has high specificity for the membrane Na
+
, K
+
-ATPase; and is responsive to relevant stimuli.
Because of their positive inotropic effect, cardiac glycosides (e.g., digitalis and ouabain) are unrivaled in value for the treatment of heart failure. Cardiac glycosides are most frequently used therapeutically to increase the adequacy of the circulation in patients with congestive heart failure and to slow the ventricular rate in the presence of atrial fibrillation and flutter.
However, cardiac glycosides have narrow therapeutic indices and their use is frequently accompanied by toxic effects that can be severe or lethal. The most important toxic effects, in terms of risk to the patient, are those that involve the heart (e.g., abnormalities of cardiac rhythm and disturbances of atrio-ventricular conduction). Gastrointestinal disorders, neurological effects, anorexia, blurred vision, nausea and vomiting are other common cardiac glycoside-induced reactions.
SUMMARY OF THE INVENTION
This invention relates to Applicant's finding that Hypothalamic Inhibitory Factor, (HIF), has a positive inotropic effect on cardiac muscle cells. The invention further relates to Applicant's finding that HIF is a potent constrictor of pulmonary artery and aortic tissue. Thus, the invention comprises, in one embodiment, a method for producing a positive inotropic effect in a mammalian host by administering to said host a positive inotropic effect-producing amount of HIF.
HIF does not manifest the same toxicity profile as the cardiac glycosides. Therefore, therapy of cardiac malfunctions with HIF can be accomplished with less risk of toxicity to the patient.
This invention further relates to the findings that HIF can be administered therapeutically to treat cardiac glycoside intoxication, edematous disorders and hypotension. Also, HIF can be used to develop specific therapies to prevent hypertension.
REFERENCES:
patent: 4001327 (1977-01-01), Lucchesi
patent: 4528190 (1985-07-01), Vale, Jr. et al.
patent: 4551426 (1985-11-01), Freytag et al.
patent: 4665019 (1987-05-01), Hamlyn et al.
patent: 4780314 (1988-10-01), Graves
patent: 5164296 (1992-11-01), Blaustein et al.
patent: 5240714 (1993-08-01), Rot
patent: 5429928 (1995-07-01), Balustein et al.
patent: WO92/04047 (1992-03-01), None
Sergio, B. et al., “effects of an Endogenous Ouabainlike Compound on Heart and Aorta”,Hypertension,17(6): Part 2:944-950 (1991).
Mathews, W.R. et al., “Mass Spectral Characterization of an Endogenous Digitalis-Like Factor From Human Plasma”,Hypertension,17(6): Part 2:930-935 (1991).
Ludens, J.H. et al., “Purification of an Endogenous digitalis-like Factor From Human Plasma for Structural Analysis”,Hypertension,17(6): Part 2: 923-929 (1991).
Hamlyn, J.M. et al., “Identification and Characterization of a ouabain-like Compound from Human Plasma”,Proc. Natl. Acad. Sci. USA,88:6259-6263 (1991).
Haber, E. and Haupert, Jr., G.T., “The Search for a Hypothalamic Na, K-ATPase Inhibitors”,Hypertension,9:315-324 (1987).
Haupert, Jr., G.T., “Overview: Physiological Inhibitors of Na, K-ATPase Concept and Status”,The Na+,K+-Pump Part B: Cellular Aspects,297-320 (1988).
Hunter, M.M. et al., “High-Affinity Monoclonal Antibodies to the Cardiac Glycoside, Digoxin”,J. Immunol.,129(3):1165-1172 (1982).
Carilli, C.T. et al., “Hypothalamic Factor Inhibits the (Na,K)ATPase from the extracellular Surface”,J. Biol.Chem.,260(2):1027-1031 (1985).
Janssens, S.P. et al., “Hypothalamic Na+, K+-ATPase Inhibitor Constricts Pulmonary Arteries of Spontaneously Hypertensive Rats”,J. Cardio. Pharm.,22(Suppl. 2):S42-S46 (1993).
Haupert, Jr., G.T. and Sancho, J.M., “Sodium transport inhibitor from bovine hypothalamus”,Proc. Natl. Acad. Sci. USA,76(9):4658-4660 (1979).
Haupert, Jr., G.T. et al., “Hypothalamic sodium-transport inhibitor is a high-affinity reversible inhibitor of Na+-K+-ATPase”, reprint fromAm. Physiol. Soc:F919-F924 (1984).
Mirsalikhova, N.M. et al., “Some Features of the Inhibition of Na+, K+-ATPase in Heart Muscle by Cardiotonic Glycosides”,Inst. Biochem. and Inst. Chem. Plant Subst., Academy of Sciences of the Urbek SSR,Tashkent, USSR, pp. 269-275.
Pitts, R.F., “Chapter 5, Clearance and Rate of Glomerular Filtration”,Physiology of the Kidney and Body Fluids(Year Book Medical Publishers Inc., 3rd Edition, Chicago, IL) :60-63.
Mudgett-Hunter, M. et al., “Binding and Structural Diversity Among High-Affinity Monoclonal Anti-Digoxin Antibodies”,Molec, Imunol.,22(4):477-488 (1985).
Smith, T.W. et al., “Tretment of Life-Threatening Digitalis Intoxication with Digoxin-Specific Fab Antibody Fragments”,The New England Journal of Medicine,307(22):1357-1362 (1982).
Smith, T.W. et al., “reversal of Advanced Digoxin Intoxication with Fab Fragments of Digoxin-Specific Antibodies”,The New England Journal of Medicine,294(1
Hamilton Brook Smith & Reynolds P.C.
Peselev Elli
The General Hospital Corporation
LandOfFree
Method for treating cardiac malfunction does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating cardiac malfunction, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating cardiac malfunction will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2509012